American Academy of Dermatology Meeting

American Academy of Dermatology Meeting

March 10, 2017
2 min read
Save

Tapinarof cream shows efficacy in treating plaque psoriasis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Tapinarof nonsteroidal anti-inflammatory topical cream, applied once or twice daily, showed efficacy in treating mild-to-moderate plaque psoriasis, according to late-breaking research presented at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Tomoko Maeda-Chubachi, MD, presented research on a randomized, evaluator-blinded study of 227 adults with psoriasis; about 80% of patients had mild-to-moderate plaque-type psoriasis. The study included a screening, 12 weeks of treatment with tapinarof topical cream (GSK2894512, GlaxoSmithKline). Tapinarof is as synthetic hydroxylated stilbene molecule that acts as an anti-inflammatory agent. No novel nonsteroidal topical therapies for psoriasis have been approved in more than 25 years, according to the researchers, with current topical options limited to corticosteroids or vitamin D analogs.

The primary endpoint was proportion of patients with physician global assessment (PGA) score of 0 or 1 (clear or almost clear) at week 12, with a minimum 2-grade improvement in 5-point PGA score from baseline to week 12. The secondary endpoint was proportion of patients achieving a 75% improvement in Psoriasis and Severity Index (PASI 75) score.

Patients were treated with 1% tapinarof cream once or twice daily, 0.5% tapinarof cream once or twice daily or vehicle once or twice daily.

There were 174 patients who completed the study.

The researchers found that 65% and 56% of patients in the twice-daily and once-daily tapinarof 1% groups, respectively, achieved the primary endpoint, as did 46% and 36% of patients in the twice-daily and once-daily tapinarof 0.5% groups, respectively. Among vehicle patients, 11% and 5% of the twice-daily and once-daily patients, respectively, reached the primary endpoint.

PASI 75 results were achieved by 65% and 56% of patients in the tapinarof 1% twice-daily and once-daily groups, respectively, and by 46% of patients in both the once-daily and twice-daily tapinarof 0.5% groups. In the vehicle group, 16% of the twice-daily group and 5% of the once-daily group achieved PASI 75.

Four weeks after discontinuation, efficacy was maintained.

Ten percent of patients in the tapinarof treatment groups and 1% of the vehicle treatment groups discontinued the study due to adverse events, with contact dermatitis being the most common adverse event leading to drug discontinuation.

Maeda-Chubachi and colleagues concluded that the 1% cream demonstrated higher efficacy than the 0.5% cream, and the 1% had quicker onset of action, with no difference between once- or twice-daily applications.

“Tapinarof cream 0.5% and 1% [once-daily] or [twice-daily] showed efficacy for plaque psoriasis in this study … [and] is generally safe and well tolerated,” Maeda-Chubachi concluded. “Tapinarof cream could be an improved treatment option over existing therapy.” – by Bruce Thiel

Reference:

Maeda-Chubachi T. F056 – Late-breaking Research Forum Clinical Trials. Presented at: American Academy of Dermatology Annual Meeting; March 3-7, Orlando.

Disclosure: Maeda-Chubachi reports being an employee of Glaxo-Smith-Kline, which sponsored the study.